Breast cancer patients with progesterone receptor PR-A-rich tumors have poorer disease-free survival rates.
about
The progestational and androgenic properties of medroxyprogesterone acetate: gene regulatory overlap with dihydrotestosterone in breast cancer cells.Post-translational modifications of the progesterone receptorsMethylsulfonylmethane suppresses breast cancer growth by down-regulating STAT3 and STAT5b pathwaysEpigenetic regulation in estrogen receptor positive breast cancer--role in treatment responseMetastasis-associated protein 2 is a repressor of estrogen receptor alpha whose overexpression leads to estrogen-independent growth of human breast cancer cellsThe effectiveness of nano chemotherapeutic particles combined with mifepristone depends on the PR isoform ratio in preclinical models of breast cancerLinkage of progestin and epidermal growth factor signaling: phosphorylation of progesterone receptors mediates transcriptional hypersensitivity and increased ligand-independent breast cancer cell growth.Extra-nuclear signaling of progesterone receptor to breast cancer cell movement and invasion through the actin cytoskeleton.Na(+) and K(+) allosterically regulate cooperative DNA binding by the human progesterone receptorMinireview: Progesterone Regulation of Proliferation in the Normal Human Breast and in Breast Cancer: A Tale of Two Scenarios?Progesterone receptor isoform functions in normal breast development and breast cancerERalpha-negative and triple negative breast cancer: molecular features and potential therapeutic approachesProgesterone receptors, their isoforms and progesterone regulated transcriptionAndrogen receptor overexpression induces tamoxifen resistance in human breast cancer cells.Differential regulation of breast cancer-associated genes by progesterone receptor isoforms PRA and PRB in a new bi-inducible breast cancer cell line.A novel functional interplay between Progesterone Receptor-B and PTEN, via AKT, modulates autophagy in breast cancer cells.Hormones, receptors, and growth in hyperplastic enlarged lobular units: early potential precursors of breast cancer.Pregnancy-associated breast cancer and metastasis.Expression of Estrogen Sulfotransferase 1E1 and Steroid Sulfatase in Breast Cancer: A Immunohistochemical StudyThe bioidentical hormone debate: are bioidentical hormones (estradiol, estriol, and progesterone) safer or more efficacious than commonly used synthetic versions in hormone replacement therapy?A steroid-conjugated magnetic resonance probe enhances contrast in progesterone receptor expressing organs and tumors in vivo.Progestin and antiprogestin responsiveness in breast cancer is driven by the PRA/PRB ratio via AIB1 or SMRT recruitment to the CCND1 and MYC promoters.Molecular drivers of lobular carcinoma in situ.Growth factor-induced resistance to tamoxifen is associated with a mutation of estrogen receptor alpha and its phosphorylation at serine 305.Association between the estrogen receptor alpha A908G mutation and outcomes in invasive breast cancer.Thermodynamic analysis of progesterone receptor-promoter interactions reveals a molecular model for isoform-specific function.The biology of progesterone receptor in the normal mammary gland and in breast cancerRole of epigenetic modifications in luminal breast cancer.A logistic regression model for predicting axillary lymph node metastases in early breast carcinoma patients.Insulin-like growth factor 1 attenuates antiestrogen- and antiprogestin-induced apoptosis in ER+ breast cancer cells by MEK1 regulation of the BH3-only pro-apoptotic protein BimIn vitro mechanism for downregulation of ER-α expression by epigallocatechin gallate in ER+/PR+ human breast cancer cellsPrognostic Significance of Single Progesterone Receptor Positivity: A Comparison Study of Estrogen Receptor Negative/Progesterone Receptor Positive/Her2 Negative Primary Breast Cancer With Triple Negative Breast Cancer.From steroid receptors to cytokines: the thermodynamics of self-associating systemsRole of the short isoform of the progesterone receptor in breast cancer cell invasiveness at estrogen and progesterone levels in the pre- and post-menopausal ranges.Role of the progesterone receptor for paclitaxel resistance in primary breast cancer.Mortality following development of breast cancer while using oestrogen or oestrogen plus progestin: a computer record-linkage study.Alternative splicing and the progesterone receptor in breast cancer.Minireview: nuclear receptors and breast cancerStrain-specific differences in the mechanisms of progesterone regulation of murine mammary gland developmentFinally! A model for progesterone receptor action in normal human breast
P2860
Q25257485-4DABB69A-90E5-4F7B-8CE3-75793229B14AQ27010251-7A33BD29-EDFF-4218-A99D-3DD1455A8DF8Q27306870-36863C12-2170-471A-9E7D-37C0E11202AEQ27694612-7FFAAE52-82E0-4C39-A255-6027010F5F7EQ28237005-25D543E1-5020-4DEC-8EF1-5961A9C4E8CEQ28540889-802AFB27-DDF4-4F8E-924F-B18F3C4D34FAQ33266857-37AD64B1-957A-403E-AA4E-C94B8CBA03CDQ33355956-5B62F3C5-2B9D-40F4-ADBA-BF9F7C77752EQ33598833-72CBF18A-0C08-4E81-B866-5DAA6B7BD877Q33631557-634AE1B9-F1C1-4119-A376-0C02C1F255DCQ33693898-7A888C62-2638-44F2-A88F-E9A403AA9538Q34119028-BACFA95B-A3FA-487F-AE98-E1F808487A78Q34219750-D16FD045-A8A1-464F-8D61-D3998354C6B0Q34369138-9EAE71F9-E5FD-4E97-A3E5-50BAEF62D16EQ34430545-A7E87270-4B05-4B35-B274-F58B0E1E1264Q34473669-3CC74601-E580-4A21-8768-819917B20D0BQ34480678-10B4C5E0-0515-4449-902D-A0A552C0ED40Q34504760-344C0083-2073-4D0F-A07B-EF7F5DE0FBFCQ34908906-1DE9E3C0-B7E5-4E23-918A-716C6AC16245Q34932849-019C940B-C0EA-4848-935A-E4EDAC9D01C1Q35141461-2E165CE7-C35F-4549-881F-99D46055E79AQ35181201-2782B634-1F21-4D8B-8EB1-C409289A22E7Q35676504-2B1EAB3B-59EB-4BE9-B56E-D45F6F00B295Q35786706-95E25A2B-FCCA-4111-AE29-DB842EC2B742Q35794355-846DF3A5-0532-49EA-BC4F-CDB01AA29704Q35844543-1EE367FE-E551-477C-811A-8B43876CF492Q35868802-79E64F11-6068-422E-A3B0-56B5DB3F1E73Q35963443-8AFFE04D-FA4A-4A00-9A9E-0832D8179ED8Q36239218-6C83B75E-30CC-49BE-94D4-A1E764E38A3CQ36245560-58A0AD0D-824A-4640-A2AD-3BF1293CDFD7Q36274172-88969B9A-1D55-4637-8B29-000C58A099C6Q36299320-500A292D-0506-44D9-9818-C3A36E61C89CQ36503592-25767B15-AA20-496B-8918-5B271150813AQ36545100-10502A61-F65D-471D-B13A-4B0A780401AAQ36609702-CA907DD9-B1EF-4FE3-BB09-49CF2732C8ABQ36615213-516E028B-E900-46A4-AEA5-B2514D5C1007Q36787349-50C73C23-21A3-4B5E-A4D4-44C5CD762531Q36971797-ABAAC610-D9A1-4150-910E-181A051ECE0AQ37125950-C0BE5705-7BAE-4A62-B27D-A4A93AA3C7A7Q37244577-797274F9-03C5-42E9-92A4-1B8E6A7DB18F
P2860
Breast cancer patients with progesterone receptor PR-A-rich tumors have poorer disease-free survival rates.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Breast cancer patients with pr ...... r disease-free survival rates.
@en
type
label
Breast cancer patients with pr ...... r disease-free survival rates.
@en
prefLabel
Breast cancer patients with pr ...... r disease-free survival rates.
@en
P2093
P1476
Breast cancer patients with pr ...... r disease-free survival rates.
@en
P2093
D Craig Allred
Heidi L Weiss
Kathryn B Horwitz
Susan G Hilsenbeck
Suzanne A W Fuqua
Torsten A Hopp
P304
P356
10.1158/1078-0432.CCR-03-0141
P407
P577
2004-04-01T00:00:00Z